Nivolumab (OpdivoTM) is a PD-1 antagonist and has been approved by FDA for the treatment of several different cancer types such as melanoma, non-small cell lung cancer, hepatocellular carcinoma, cervical cancer and head and neck squamous cell carcinoma (FDA: Hematology/oncology (cancer) approvals & safety notifications. The gene discussed is SNCA; the disease is cancer.